A brain-derived peptide that modulates cannabinoid receptors reduced food intake in rats without causing weight loss
RVD-hemopressin(alpha), a naturally occurring brain peptide that negatively modulates CB1 receptors, reduced food intake in rats over 14 days but did not change body weight, possibly because it simultaneously reduced energy expenditure.
Quick Facts
What This Study Found
Daily injections of RVD-hemopressin(alpha) (10 nmol) for 14 days reduced food intake in rats. However, body weight was unaffected despite the decreased eating. The researchers found that this paradox may be explained by decreased expression of UCP-1 (uncoupling protein 1) in brown adipose tissue, which would reduce thermogenic energy expenditure, offsetting the caloric deficit from eating less.
At the brain level, RVD-hemopressin(alpha) downregulated POMC gene expression and norepinephrine levels in the hypothalamus, providing a neuromodulatory mechanism for the appetite effects.
Key Numbers
RVD-hemopressin(alpha) 10 nmol daily for 14 days. Decreased food intake. No body weight change. Decreased UCP-1 in brown adipose tissue. Decreased POMC and norepinephrine in hypothalamus.
How They Did This
Rats received 14 daily intraperitoneal injections of RVD-hemopressin(alpha) (10 nmol). Food intake and body weight were monitored. Brain tissue was analyzed for POMC gene expression and norepinephrine levels. Brown adipose tissue was assessed for UCP-1 gene expression.
Why This Research Matters
The brain produces its own peptides that modulate cannabinoid receptors. Understanding how these natural regulators affect appetite and metabolism could lead to more physiological approaches to treating obesity, working with the body's own cannabinoid control systems rather than against them.
The Bigger Picture
The disconnect between reduced food intake and stable body weight reveals that appetite and metabolism are linked through the cannabinoid system. Simply reducing eating through cannabinoid modulation may be counteracted by metabolic slowdown, a finding relevant to any weight-loss strategy targeting the endocannabinoid system.
What This Study Doesn't Tell Us
Animal study with direct peptide injection. The peptide likely does not cross the blood-brain barrier well, limiting its therapeutic potential. Only 14 days of treatment were assessed. The absence of weight loss despite reduced eating limits the translational value for obesity treatment.
Questions This Raises
- ?Could the metabolic compensation be overcome with combination therapies?
- ?Would longer treatment eventually produce weight loss?
- ?Do humans produce similar cannabinoid-modulating peptides with comparable appetite effects?
Trust & Context
- Key Stat:
- Reduced food intake but no weight loss: metabolic compensation offset caloric deficit
- Evidence Grade:
- Animal study using injected peptides. Provides mechanistic insight but limited by the non-physiological delivery route and absence of the desired weight loss outcome.
- Study Age:
- Published in 2017. Research on endogenous cannabinoid-modulating peptides and their metabolic effects continues.
- Original Title:
- Anorexigenic effects induced by RVD-hemopressin(α) administration.
- Published In:
- Pharmacological reports : PR, 69(6), 1402-1407 (2017)
- Authors:
- Ferrante, Claudio(2), Recinella, Lucia(2), Leone, Sheila(2), Chiavaroli, Annalisa, Di Nisio, Chiara, Martinotti, Sara, Mollica, Adriano, Macedonio, Giorgia, Stefanucci, Azzurra, Dvorácskó, Szabolcs, Tömböly, Csaba, De Petrocellis, Luciano, Vacca, Michele, Brunetti, Luigi, Orlando, Giustino
- Database ID:
- RTHC-01376
Evidence Hierarchy
Tests effects in animals (usually mice or rats), not humans.
What do these levels mean? →Frequently Asked Questions
Why didn't the rats lose weight if they ate less?
The peptide reduced UCP-1 expression in brown fat, which decreases the body's heat production and energy expenditure. This metabolic slowdown appears to have compensated for the reduced caloric intake, maintaining stable body weight.
What is RVD-hemopressin?
It is a naturally occurring peptide in the brain derived from hemoglobin. It acts as a negative allosteric modulator of CB1 cannabinoid receptors, meaning it reduces CB1 activity without completely blocking the receptor.
Read More on RethinkTHC
- cannabis-cardiovascular-heart-risk-stroke
- cannabis-heart-cardiovascular-risk
- coughing-up-stuff-after-quitting-weed
- lung-recovery-after-quitting-smoking-weed
- lung-recovery-quitting-weed
- quitting-weed-female-hormones
- quitting-weed-weight-gain-loss-diet-appetite
- sex-after-quitting-weed
- weed-DUI-driving-impaired-cannabis-laws
- weed-acne-skin
- weed-fertility-sperm
- weed-gut-digestion-problems
- weed-heart-health
- weed-testosterone-levels
Cite This Study
https://rethinkthc.com/research/RTHC-01376APA
Ferrante, Claudio; Recinella, Lucia; Leone, Sheila; Chiavaroli, Annalisa; Di Nisio, Chiara; Martinotti, Sara; Mollica, Adriano; Macedonio, Giorgia; Stefanucci, Azzurra; Dvorácskó, Szabolcs; Tömböly, Csaba; De Petrocellis, Luciano; Vacca, Michele; Brunetti, Luigi; Orlando, Giustino. (2017). Anorexigenic effects induced by RVD-hemopressin(α) administration.. Pharmacological reports : PR, 69(6), 1402-1407. https://doi.org/10.1016/j.pharep.2017.05.015
MLA
Ferrante, Claudio, et al. "Anorexigenic effects induced by RVD-hemopressin(α) administration.." Pharmacological reports : PR, 2017. https://doi.org/10.1016/j.pharep.2017.05.015
RethinkTHC
RethinkTHC Research Database. "Anorexigenic effects induced by RVD-hemopressin(α) administr..." RTHC-01376. Retrieved from https://rethinkthc.com/research/ferrante-2017-anorexigenic-effects-induced-by
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkTHC research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.